BeyondSpring Inc Stock News

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today an

BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q4 2020 Results - Earnings Call Transcript

- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemothera

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative can

– Applications are supported by positive PROTECTIVE-2 Phase 3 data demonstrating that plinabulin in combination with G-CSF offers greater protection against CIN than the standard of care, G-CSF alon

Today, we take an in-depth look at BeyondSpring, a small cap concern focused on the development of immuno-oncology cancer therapies. In recent months, the company has addressed its current funding nee

Webinar on Thursday, March 18 th @ 10:00 a.m. ET

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer th

BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.

- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer t